+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Handling of gene-transfer products by the National Institutes of Health Clinical Center pharmacy department



Handling of gene-transfer products by the National Institutes of Health Clinical Center pharmacy department



American Journal of Health-System Pharmacy 54(14): 1604-1610



Policies and procedures for handling gene-transfer products at the National Institutes of Health (NIH) Clinical Center pharmacy department are described. The pharmacy at the Clinical Center is responsible for handling in vivo gene-transfer delivery systems, which are gene-transfer products that are prepared for direct administration to patients. The gene-transfer products currently handled by the pharmacy are investigational and are composed of viruses containing the gene encoding either of the melanoma antigens MART-1 and gp100. The pharmacy has prepared guidelines, based on the principles of aseptic technique and FDA guidelines for manufacturing facilities, intended to help pharmacy personnel safely dilute a concentrated gene-transfer product into a dose suitable for administration. Before a product is handled, the biological safety level is determined and a biohazard sign is posted. Worksheets detailing all supplies, calculations for dilutions, and procedures that will be required are prepared in advance; the worksheets are part of a drug fact sheet prepared for all investigational drugs dispensed. Personnel must be properly trained and dressed in protective clothing. Aseptic technique and decontamination procedures are used as specified in the guidelines, and all materials used are disposed of as biohazardous waste. All work is documented. If a worker is accidentally exposed, standard procedures are followed. The handling of gene-transfer products at the NIH Clinical Center pharmacy is based on the principles of aseptic technique, FDA guidelines, and experience.

(PDF emailed within 0-6 h: $19.90)

Accession: 046211480

Download citation: RISBibTeXText

PMID: 9248603

DOI: 10.1093/ajhp/54.14.1604


Related references

National Institutes of Health Clinical Center Pharmacy. Journal of the American Pharmaceutical Association 15(5): 292-295, 1954

The Clinical Center Nursing Department at the National Institutes of Health (NIH) Bethesda, MD. Nursing Spectrum 4(23): 7-7, 1994

Technology advancement for studying gene expression and gene function: a workshop report. Sponsored by National Institute of Child Health and Human Development, National Institute of General Medical Sciences, National Center for Human Genome Research, National Center for Research Resources, National Institutes of Health, Bethesda, Maryland 20892, USA. Mammalian Genome 5(3): 127-130, 1994

NATIONAL Institutes of Health and Clinical Center. Medical Times 86(8): 1018-1021, 1958

Clinical Toxicology, Department of Clinical Pharmacy, Center for Clinical Pharmacy and Clinical Sciences, School of Pharmacy, Kitasato University. Chudoku Kenkyu 23(4): 319-321, 2011

Research in the clinical center of the National Institutes of Health. Southern Medical Journal 47(3): 257-265, 1954

The Clinical Center, National Institutes of Health, U.S. Public Health Service. Military Surgeon 114(5): 351-356, 1954

Pharmacogenomics Implementation at the National Institutes of Health Clinical Center. Journal of Clinical Pharmacology 57 Suppl 10: S67-S77, 2018

National Institutes of Health Clinical Center hosts Clinical Investigator Student Trainee Forum. Journal of Investigative Medicine 55(1): 8-9, 2007

Revitalization of the Warren G. Magnuson Clinical Center at the National Institutes of Health. Academic Medicine 73(5): 460-466, 1998

National Institutes of Health, Warren Grant Magnuson Clinical Center. Asha 41(4): 46-49, 1999

National Institutes of Health. Report calls for smaller clinical center. Science 263(5154): 1678, 1994

Development of a Reversible Vas Deferens Occlusive Device. Ii Effect of Bilateral and Unilateral Vasectomy on Semen Characteristics in the Dog**Supported by the Contraceptive Development Branch, Center for Population Research, National Institutes of Child Health and Human Development, National Institutes of Health, Contract No. Nih-Nichd-71-2229. Fertility and Sterility 25(8): 673-686, 1974

Investigator initiated multi-center clinical trials and the national institutes of health. Controlled Clinical Trials 1(2): 179-180, 1980

The Clinical Center of medical research, National Institutes of Health, Bethesda, Maryland, USA. Concours Medical 76(8): 777-778, 1954